Investigational Only. Product candidates are investigational and not approved by the FDA or Health Canada. Content is non-promotional and for informational / investor-relations purposes only. Third-party marks (e.g., CVS, Walgreens) are the property of their respective owners and are referenced nominatively only. No affiliation or endorsement is implied.
Investor Materials
Confidential materials. Not for promotional use. U.S. audience.
Executive Summary
Company:
Pantarhin Pharma Inc., Tampa, Florida (organized May, 2025)
Modality:
Enzyme therapeutics (D016) for cardiovascular health — investigational, FDA-unapproved.
Access Strategy (U.S.):
Dual-channel via retail pharmacy partners (e.g., CVS, Walgreens) and physician-guided care.
Therapy Unit Economics:
Vials of 15,000 IU; therapy cycle per patient: 300-450,000 IU.
Market Model (Illustrative)
Target Specialties:
Cardiology; Internal Medicine
Illustrative Volumes:
Unit: IU / Scenario-based volumes for planning.
Packaging:
Vials (15,000 IU); SOPs/logistics per product specifics.
Figures are illustrative; not guidance. Detailed model under NDA.
U.S. Patents & Applications
The under Applications listed are acitve or under license and/or pending.
Prosecution status may evolve; no freedom-to-operate or regulatory approval is implied. No freedom-to-operate or regulatory approval is implied. Jurisdictional scopes may differ.
Downloads
By downloading, you acknowledge the non-promotional and confidential nature of these materials.
Contact / Diligence
For diligence requests and data room access (NDA), contact:
Investor Relations: IR@pantarhin.com
Forward-looking statements involve risks and uncertainties. Content provided “as is”, for information only.